Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase 7 (PTK7)-targeting antibody-drug conjugate (ADC), LY-4175408, being ...
Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback